

**Date:** 28 January 2026

<b>BSE Limited</b> Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001 <b>Scrip Code:</b> 544292	<b>National Stock Exchange of India Limited</b> Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 <b>Symbol:</b> ONESOURCE
--	---

Dear Sir/Madam,

**Subject: Disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 and Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.**

**Promoter entity (Tenshi Pharmaceuticals Private Limited), has purchased 200,000 equity shares of OneSource Specialty Pharma Limited, from the market, on January 28, 2026.**

Dear Sir/ Madam,

We are pleased to inform you that M/s. Tenshi Pharmaceuticals Private Limited, a promoter entity of the Company, has acquired 200,000 equity shares representing 0.17% of equity share capital of OneSource Specialty Pharma Limited (the “Company”), from the market, on January 28, 2026.

Relevant disclosure as received from Tenshi Pharmaceuticals Private Limited, is attached as below:

- a) Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.
- b) Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.

This is for your information and records.

For **OneSource Specialty Pharma Limited**

**Trisha A**  
Company Secretary & Compliance Officer  
Membership No.: A47635

January 28, 2026

To,

BSE Limited Corporate Relationship Dept., 1 <sup>st</sup> Floor, New Trading Ring, Rotunga Building, P.J. Towers, Dalal Street, Fort, Mumbai- 400001	National Stock Exchange of India Limited Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai - 400051
Scrip Code: 544292	Scrip Code: ONESOURCE

Dear Sir/Madam,

**Sub: Disclosure Under Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (the "Takeover Regulations")**

Pursuant to Regulation 29(2) of the Takeover Regulations, kindly find enclosed herewith the disclosure in the prescribed format with respect to purchase of equity shares held by the promoter and promoter group.

Kindly take the same on record.

Thank you,

For Tenshi Pharmaceuticals Private Limited



Shridhara Kela  
Director  
DIN: 02592314  
Pranam, 1211 5<sup>th</sup> Cross Road, BDA Layout,  
BTM 4<sup>th</sup> Stage 2<sup>nd</sup> Block, Near Electronic city RTO office,  
Devarachikkannahalli, Bangalore Karnataka – 560076  
January 28, 2026

Copy to: Trisha A  
Company Secretary and Compliance Officer  
Unit No. 902, Cyber OnePlot No – 4 & 6,  
Sector 30A, Vashi, Navi Mumbai, Sanpada, Thane,  
Thane, Maharashtra, India, 400703

---

**Tenshi Pharmaceuticals Private Limited**

**Registered Office:** 'Karuna House' First Floor, Sy No 152/6 & 154/16. Dorasani palya, Begur Hobli,  
Bannerghatta Road, Bengaluru-560076, Karnataka, India  
Tel.: +91 8029916826 | E-mail: [secretarial@tenshi.co.in](mailto:secretarial@tenshi.co.in) | CIN: U70200KA2016PTC200180

Format for Disclosures under Regulation 29(2) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Onesource Speciality Pharma Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Acquirer: Tensi Pharmaceuticals Private Limited PAC: Karuna Business Solutions LLP Pronomz Ventures LLP Arco Lab Private Limited Arun Kumar Pillai Vineetha Mohanakumar Pillai Padmakumar Karunakaran Pillai Sajitha Pillai Rajitha Gopalakrishnan Aditya Arun Kumar Hemalatha Pillai		
Whether the acquirer belongs to Promoter/Promoter group	Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited and National Stock exchange of India Limited		
Details of the acquisition as follows	Number	% w.r.t. total share/voting capital	% w.r.t. total diluted share/voting capital of the TC (**)
<b>Before the acquisition under consideration, holding of acquirer along with PACs of:</b>			
a) Shares carrying voting rights	3,42,96,199	29.93	29.33
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)			
c) Voting rights (VR) otherwise than by shares			
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)			
e) Total (a+b+c+d)	3,42,96,199	29.93	29.33
<b>Details of acquisition</b>			
a) Shares carrying voting rights acquired	2,00,000	0.17	0.17
b) VRs acquired otherwise than by shares			
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)			
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)			
e) Total (a+b+c+/-d)	2,00,000	0.17	0.17

**Tensi Pharmaceuticals Private Limited**

**Registered Office:** 'Karuna House' First Floor, Sy No 152/6 & 154/16. Dorasani palya, Begur Hobli, Bannerghatta Road, Bengaluru-560076, Karnataka, India  
 Tel.: +91 8029916826 | E-mail: [secretarial@tensi.co.in](mailto:secretarial@tensi.co.in) | CIN: U70200KA2016PTC200180

After the acquisition, holding of acquirer along with PACs of:			
a) Shares carrying voting rights b) VRs otherwise than by equity shares c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others) e) Total (a+b+c+d)	3,44,96,199	30.10	30.10
Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer/encumbrance, etc.)	Open Market		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	Equity Shares		
Date of acquisition of/ date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.	January 28, 2026		
Equity share capital / total voting capital of the TC before the said acquisition	11,45,62,136 equity shares of Rs. 1 each, fully paid up		
Equity share capital/ total voting capital of the TC after the said acquisition	11,45,62,136 equity shares of Rs. 1 each, fully paid up		
Total diluted share/voting capital of the TC after the said acquisition	11,45,62,136 equity shares of Rs. 1 each, fully paid up		


**Note:**

(\*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(\*\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

For Tenshi Pharmaceuticals Private Limited

Signature of Director:



Shridhara Kela  
Director (DIN:02592314)

Place: Bangalore

Date: January 28, 2026

**Tenshi Pharmaceuticals Private Limited**

**Registered Office:** 'Karuna House' First Floor, Sy No 152/6 & 154/16. Dorasani palya, Begur Hobli, Bannerghatta Road, Bengaluru-560076, Karnataka, India  
Tel.: +91 8029916826 | E-mail: [secretarial@tenshi.co.in](mailto:secretarial@tenshi.co.in) | CIN: U70200KA2016PTC200180

January 28, 2026

To,  
Trisha A  
Onesource Specialty Pharma Limited  
Company Secretary and Compliance Officer  
Unit No. 902, Cyber OnePlot No – 4 & 6,  
Sector 30A, Vashi, Navi Mumbai, Sanpada, Thane,  
Thane, Maharashtra, India, 400703

Dear Sir/Madam,

**Sub: Disclosure Under Regulation SEBI (Prohibition of Insider Trading) Regulations, 2015 [Regulation 7(2) read with Regulation 6(2)] (the “PIT Regulations”]**

Pursuant to Regulation 7(2) of the PIT Regulations, kindly find enclosed herewith the disclosure in the prescribed format with respect to purchase of equity shares held by the promoter and promoter group.

Kindly take the same on record.

Thank you,

**For Tenshi Pharmaceuticals Private Limited**



Shridhara Kela  
Director  
DIN: 02592314  
Pranam, 1211 5th Cross Road, BDA Layout,  
BTM 4th Stage 2nd Block, Near Electronic city RTO office,  
Devarachikkannahalli, Bangalore Karnataka – 560076  
January 28, 2026

---

**Tenshi Pharmaceuticals Private Limited**

**Registered Office:** ‘Karuna House’ First Floor, Sy No 152/6 & 154/16. Dorasani palya, Begur Hobli,  
Bannerghatta Road, Bengaluru-560006, Karnataka, India  
Tel.: +91 8029916826 | E-mail: [secretarial@tenshi.co.in](mailto:secretarial@tenshi.co.in) | CIN: U70200KA2016PTC200180

**FORM C**

**SEBI (Prohibition of Insider Trading) Regulations, 2015**  
**[Regulation 7(2) read with Regulation 6(2) – Continual disclosure]**

Name of the company: One source Specialty Pharma Limited  
 ISIN of the company: INE013P01021

**Details of change in holding of Securities of Promoter, Member of the Promoter Group, Designated Person or Director of a listed company and immediate relatives of such persons and other such persons as mentioned in Regulation 6(2).**

Name, PAN, CIN/DIN, & address with contact nos.	Category of Person (Promoters/ member of the promoter group/designated person/ Director s/ immediate relative to/others etc.)	Securities held prior to acquisition/ disposal	Securities acquired/ Disposed	Securities held post-acquisition/ disposal	Date of allotment advice/ acquisition of shares/ sale of shares specify	Date of intimation to company	Mode of acquisition / disposal (on market/public/ rights/ preferential offer / off market/ Inter- se transfer, ESOPs etc.)	Exchange on which the trade
				Type of securities (For eg. – Shares, Warrants, Debentures, Convertible Rights, entitlements etc.)	No. and % (For eg. – No shareholding)	Transac- tion Type (Purcha- se/sale Pledge Debentures, Convertible Rights, Revocat ion / entitlement, etc.)		
					No. and % of shareholding	From To		

# TENSHI

PHARMACEUTICALS

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
Name: Tenshi Pharmaceuticals Private Limited PAN: AAXCS2968P CIN: U70200KA2016PTC200180	Promoter	Equity Shares 714 shares and 17.91%	2,05,24, 714 shares and 17.91%	Equity Shares 2,00, 000	Rs. 2,0,779 ,011.10	Buy	Equity Shares 2,0724,714 and 18.09%	10 January 28, 2026	11 January 28, 2026	12 January 28, 2026	13 January 28, 2026	14 On Market	National Stock Exchange of India Limited	

**Note:** "Securities" shall have the meaning as defined under regulation 2(1)(i) of SEBI (Prohibition of Insider Trading) Regulations, 2015.

[Tenshi Pharmaceuticals Private Limited](#)

**Registered Office:** 'Karuna House' First Floor, Sy No 152/6 & 154/16, Dorasani palya, Begur Hobli, Bannerghatta Road, Bengaluru-560076, Karnataka, India  
Tel.: +91 8029916826 | E-mail: [secretarial@tenshi.co.in](mailto:secretarial@tenshi.co.in) | CIN: U70200KA2016PTC200180


**Details of trading in derivatives on the securities of the company by Promoter, member of the promoter group, designated person or Director of a listed company and immediate relatives of such persons and other such persons as mentioned in Regulation 6(2).**

Trading in derivatives (Specify type of contract, Futures or Options etc)

Type of contract	Contract specifications	Buy		Sell		Exchange on which the trade was executed
		Notional Value	Number of units (contracts * lot size)	Notional Value	Number of units (contracts * lot size)	
16	17	18	19	20	21	
						22

*Note: In case of Options, notional value shall be calculated based on Premium plus strike price of options.*

For Tenshi Pharmaceuticals Private Limited



Shridhara Kela

Director

DIN: 02592314

Pranam, 1211 5th Cross Road, BDA Layout,  
BTM 4th Stage 2nd Block, Near Electronic city RTO office,  
Devarachikkannahalli, Bangalore Karnataka – 560076  
January 28, 2026